ASCO 2025 | Multiple myeloma highlights from ASCO 2025

It has been a brilliant ASCO 2025 in Chicago for myeloma researchers and patients. We have seen a confirmation of several data in terms of MRD negativity in transplant-eligible and not-eligible frontline patients, particularly from IsKia and PERSEUS in transplant-eligible and CEPHEUS and IMROZ in transplant-ineligible patients. And I think that the new ambition will be more and more to obtain MRD negativity as a real endpoint in frontline patients. In terms of relapsed and refractory patients, we have seen many confirmations. I think the outstanding data comes from the CARTITUDE-1 trial, which we have seen 33% progression-free survival at five years. In my opinion, this is outstanding data if we consider the setting and the characteristics of the patients. Another really brilliant opportunity is the subcutaneous administration of isatuximab. We have seen a couple of trials, the [inaudible] Phase II in combination with carfilzomib and dexamethasone and the ICARIA phase 3 in combination with pomalidomide and dexamethasone. In ICARIA we have collaborated with many patients from my institution and I think the idea of non-inferiority in terms of effectiveness but superiority in terms of comfort and quality of life makes the subcutaneous administration of Isatuximab a wonderful opportunity for our patients that should be integrated as soon as possible also in the new triplet that we are going to use in our frontline patients and not only in the combination in relapsed/refractory. Isatuximab is becoming more and more an important backbone in the fight against multiple myeloma. What about the novel cellular therapies? We have seen not only CARTITUDE-1 but also BCMA-specific antibodies, incredible data, new combination with elranatamab and linvoseltamab, particularly the combination with carfilzomib. Maybe we can imagine to extend to new generation studies in order to confirm the idea of combining BCMA-CD3 bispecific antibodies with carfilzomib, also in Phase III trials. We have seen an indirect analysis of linvoseltamab versus elranatamab with the superiority of linvoseltamab. So I think that the best has yet to come in order to understand which is the best in terms of effectiveness and tolerability. And I think that also we have seen incredible data from the real world. Bispecific antibodies are showing their feasibility also in community centers in terms of effectiveness, tolerability, and management. And I think that in this moment they are really concrete in helping us to treat also really difficult-to-treat patients. What about really difficult-to-treat settings of patients? We have seen the belantamab mafodotin in combination with bortezomib and dexamethasone, DREAMM-7 subanalysis in high-risk cytogenetic patients. And I think this data is really brilliant and we are in front of a potential new standard of care in second-line patients affected by multiple myeloma. We have seen also really nice analysis in terms of profiling of our patients. Also from our institution, we have shown data in combination of whole-body MRI with PET-CT and the new molecular analysis with scFv2 and the series of multi-omic analysis with the idea of developing a prognostic score which helps us to optimize the management of our patients affected by smoldering multiple myeloma frontline or relapsed or refractory setting. All these novelties tell that ASCO has become an important appointment for hematologists, in particular for myelomologists. And I think that considering all of the novelties that we are going to see month by month, conference by conference, the cure of multiple myeloma is not far anymore. And this is the best wish that we give to our patients, to their caregivers, and to all myeloma researchers. Thank you for your attention.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.